The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of the cervix, or Kaposi's sarcoma.
• •Significant cardiac disease or CNS lesions or other neurologic abnormalities.
• •Score of \> 0.5 on ACTG AIDS Dementia Complex staging.
• •Major organ allograft.
• •Intolerance to AZT at 500 mg/day.
• •Concurrent Medication:
• •Excluded:
• •Antihypertensive medication other than diuretics.
• •Chemotherapy, hormonal therapy, or other immunotherapy.
• •Other investigational drugs, agents, or devices.
• •Beta-blockers.
• •Non-topical steroids.
• •Concurrent Treatment:
• •Excluded:
• •Radiation therapy.
• •Prior Medication:
• •Excluded:
• •Known anti-HIV medication (other than AZT) or known immunomodulators (e.g., systemic steroids, interferons, interleukins) or other chemotherapy within 30 days prior to study entry.
• •Prior Treatment:
• •Excluded:
• •Transfusion within 4 weeks prior to study entry.
• •Radiation within 30 days prior to study entry.
• •Active substance abuse.